Cargando...
Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru
Author(s)
De-Los-Rios-Pinto, Abraham
National University of Saint Anthony the Abbot in Cuzco
Fernandez‐Guzman, Daniel
Universidad San Ignacio de Loyola
Soriano‐Moreno, David R.
Sangster-Carrasco, Lucero
Peruvian University of Applied Sciences
Morocho-Alburqueque, Noelia
Universidad Nacional de Piura
Pinedo-Soria, Antony
Universidad Nacional de San Martín
Murrieta-Ruiz, Valentina
Universidad Nacional de la Amazonía Peruana
Diaz-Corrales, Angelica
Universidad de San Martín de Porres
Nieto-Gutierrez, Wendy
Universidad San Ignacio de Loyola
Gonzales-Zamora, Jose
University of Miami
Date Issued
7 de abril de 2022
Type
Article
Volume
40
Issue
26
Series/Report No.
Vaccine
Start Page
3566
End Page
3572
ISSN
0264-410X
1873-2518
Abstract
Objective To evaluate the factors associated with the intention to participate in COVID-19 vaccine clinical trials in the Peruvian population. Methods Cross-sectional study and secondary analysis of a database that involved Peruvian population during September 2020. The Poisson regression model was used to estimate the associated factors. Results Data from 3231 individuals were analyzed, 44.1% of whom intended to participate in COVID-19 vaccine clinical trials. Factors associated with the outcome were being male (RPa: 1.25; 95% CI: 1.15-1.35), being from the highlands region (RPa: 1.18; 95% CI: 1.09-1.28) or jungle (RPa: 1.30; 95% CI: 1.15-1.47), having a relative that is a healthcare professional (PRa: 1.16; 95% CI: 1.06-1.28), using a medical source of information (PRa: 1.28; 95% CI: 1.17-1.41), and trusting in the possible effectiveness of vaccines (PRa: 1.40; 95% CI: 1.29-1.51). The main reason for not participating in the trial was the possibility of developing side effects (69.80%). Conclusion There is an urgent need to generate a perception of safety in COVID-19 vaccine clinical trials, to increase the population's intention to participate in these studies, and to provide evidence-based information about the vaccine.